Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biontech Se ADR (NQ: BNTX )

118.02 +4.89 (+4.32%)
Streaming Delayed Price Updated: 1:44 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biontech Se ADR

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Exposures Product Safety
The Analyst Landscape: 17 Takes On BioNTech
Via Benzinga
What Analysts Are Saying About BioNTech Stock
Via Benzinga
Breaking Down BioNTech: 16 Analysts Share Their Views
Via Benzinga
Forecasting The Future: 15 Analyst Projections For BioNTech
Via Benzinga
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
Exposures Political
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding its oncology and R&D presence in China. 
Via Benzinga
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus. 
Via Benzinga
This Bank of America Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda. 
Via Benzinga
Topics Government
Exposures Political
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript
BNTX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward. 
Via Benzinga
Exposures COVID-19
BioNTech Jumps On Surprise Profit, Wide Sales Beat; But Lowers Outlook
The company now expects sales to come in at the lower end of its previous guidance. 
Via Investor's Business Daily
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy. 
Via The Motley Fool
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment
BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current participants continue treatment, and other trials remain unaffected. 
Via Benzinga
Exposures Product Safety
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines. 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake
Shares peaked near 62 in late 2021, but are now worth less than half of that. 
Via Investor's Business Daily
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Consumer Tech News (Sept 30-Oct 4): Latest Windows 11 Update Causing Trouble, Apple Accused Of Compelling Employees To Sign Illegal Agreements & More
Major tech companies lobby against CA bill regulating AI, Apple faces legal complaints, iPhone users retain devices longer. Google warns Apple app removal. 
Via Benzinga
Topics Artificial Intelligence Law Enforcement
Exposures Artificial Intelligence Legal
Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research
This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
Via Investor's Business Daily
Here's Why Everyone's Talking About Summit Therapeutics
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.